Dobutamine for patients with end-stage heart failure in a hospice program?

Journal of Palliative Medicine

Volumn 6, Issue 1, 2003, Pages 93-97

  Rich, Michael W ^a   Shore, Bernard L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUMETANIDE; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENALAPRIL; GLYCERYL TRINITRATE; ISOSORBIDE 5 NITRATE; LORAZEPAM; MILRINONE; MORACIZINE; MORPHINE; NESIRITIDE; NITROPRUSSIDE SODIUM; SPIRONOLACTONE; WARFARIN;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG ACTIVITY; DRUG MECHANISM; DYSPNEA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HOSPICE; HUMAN; HYPOTENSION; MALE; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; TACHYCARDIA; TERMINAL CARE; TREATMENT OUTCOME;

EID: 0037308631     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/10966210360510190     Document Type: Article

References (12)

1. American Heart Association: 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 2001.
2. Kannel WB, Belanger AJ: Epidemiology of heart failure. Am Heart J 1991;121:951-957.
3. Popovic JR: 1999 National Hospital Discharge Survey: annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 2001(151):i-v, 1-206.
4. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ: More "malignant" than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001;3:315-322.
5. Cohn JN: The management of chronic heart failure. N Engl J Med 1996;335:490-498.
6. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38:2101-2113.
7. Krell MJ, Kline EM, Bates ER, Hodgson JM, Dilworth LR, Laufer N, Vogel RA, Pitt B: Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 1986;112:787-791.
8. Marius-Nunez AL, Heaney L, Fernandez RN, Clark WA, Ranganini A, Silber E, Denes P: Intermittent inotropic therapy in an outpatient setting: a cost effective therapeutic modality in patients with refractory heart failure. Am Heart J 1996;132:805-808.
9. O'Connor CM, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999;138: 78-86.
10. Elis A, Bental T, Kimchi O, Ravid M, Lishner M: Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther 1998;63:682-685.
11. National Hospice and Palliative Care Organization: Medical Guidelines for Non-Cancer Diagnoses, 2nd ed. Arlington, VA: National Hospice and Palliative Care Organization, 1996.
12. Fox E, Landrum-McNiff K, Zhong Z, Dawson NV, Wu AW, Lynn J: Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. JAMA 1999;282: 1638-1645.